Overview

Systemic Pharmacokinetics of BOL-303224-A

Status:
Completed

Trial end date:
2007-10-01

Target enrollment:

Participant gender:

Summary

This is a multi-center, open-label, single dose/multiple dose, pharmacokinetic study in participants with bacterial conjunctivitis. The purpose of this study is to determine the extent of systemic exposure to BOL-303224-A following single and multiple topical administration of BOL-303224-A in participants with suspected bacterial conjunctivitis.

Phase:

Phase 1

Details

Lead Sponsor:

Bausch & Lomb Incorporated

Treatments:

7-(3-aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
Besifloxacin
Fluoroquinolones